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Weight loss ≥ 5 percent is sufficient to significantly reduce 
health risks for obese people; therefore, development of novel 
weight loss compounds with reduced toxicity is urgently 
required. After screening of natural compounds with anti- 
adipogenesis properties in 3T3-L1 cells, we determined that 
kahweol, a coffee-specific diterpene, inhibited adipogenesis. 
Kahweol reduced lipid accumulation and expression levels of 
adipogenesis and lipid accumulation-related factors. Levels of 
phosphorylated AKT and phosphorylated JAK2, that induce 
lipid accumulation, decreased in kahweol-treated cells. 
Particularly, kahweol treatment significantly increased AMP- 
activated protein kinase (AMPK) activation. We revealed that 
depletion of AMPK alleviated reduction in lipid accumulation 
from kahweol treatment, suggesting that inhibition of lipid 
accumulation by kahweol is dependent on AMPK activation. 
We detected more rapid reduction in blood glucose levels in 
mice administrated kahweol than in control mice. We suggest 
that kahweol has anti-obesity effects and should be studied 
further for possible therapeutic applications. [BMB Reports 
2017; 50(11): 566-571]
INTRODUCTION
Obesity is a disease that is becoming a global issue. Obesity 
increases the risk of mortality and morbidity, because it is 
accompanied by hypertension, heart disease, type 2 diabetes, 
and some types of cancer (1). Pharmacotherapeutic drugs have 
been developed and used for treating obesity. According to 
meta-analysis about effects of anti-obesity drugs approved by 
the Food and Drug Administration (FDA), anti-obesity drugs 
promote moderate weight loss (2). Initially, the thyroid 
hormone was selected as a therapeutic target, and 
Amphetamine became popular for an appetite suppressant in 
the late 1930s (3). Sibutramine was approved for long-term 
treatment in 1997. Orlistat was approved by the FDA for 
long-term treatment in 1999. It reduces intestinal fat 
absorption by inhibiting gastric and pancreatic lipases that 
hydrolyze triglyceride. The latest approved anti-obesity drugs 
were liraglutide and bupropion-naltrexone in 2014 (3). 
The Endocrine Society suggests use of approved anti-obesity 
drugs to preserve long-term weight improves complications of 
obesity and increases adaptation to behavioral modification 
(4). However, safety concerns for anti-obesity drugs have 
emerged, and some drugs have been removed from the 
market. For example, dexfenfluramine, associated with cardio-
vascular side effects was withdrawn from FDA approval in 
1997. Sibutramine also provokes severe cardiovascular events 
(5). Moreover, even with current drugs on the market such as 
orlistat, bupropion-naltrexone, phentermine-topiramate and 
liraglutide, treatment decisions are driven by co-existing 
medical conditions (6). For example, liraglutide may be a 
more relevant agent in individuals with type 2 diabetes 
because it lowers blood glucose levels. The use of bupropion- 
naltrexone in patients with alcohol or opioid dependence is 
associated with neuropsychiatric complications (7). Finally, the 
U.S. Drug Enforcement Administration (DEA) has classified 
most anti-obesity drugs as controlled substances, and many 
states have passed strict regulations relative to prescriptions 
and use. 
Even if only 5 percent of weight is lost, the risk of metabolic 
disorders such as type 2 diabetes, non-alcoholic fatty liver 
disease or hypertension is significantly reduced (8). The goal of 
anti-obesity drugs is to enable weight loss of more patients. A 
barrier to drug approval is not only individuals with health 
risks but also healthy individuals that may use anti-obesity 
drugs which may lead to serious side effects. Low side-effects 
from drugs are essential for approval (1, 9, 10).
Consequently, the primary objective of our research was to 
identify anti-obesity drugs by screening natural products, 
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Fig. 1. Kahweol inhibits lipid accumulation in 3T3-L1 cells, 
whereas cafestol has no effect on lipid accumulation. (A) Structure 
of kahweol. (B) Structure of cafestol. (C, D) Oil Red O staining 
of kahweol- and cafestol-treated 3T3-L1 cells. After MDI induction, 
3T3-L1 cells were treated with kahweol or cafestol on days 2-6. 
Oil Red O staining was performed on day 6. Measurement of 
lipid accumulation. Stained ORO was eluted with 100 percent 
isopropanol and measured using the OD500. ***P ＜ 0.001, 
DMSO vs. kahweol, DMSO vs. cafestol. (E) Cell viability assays. 
Confluent 3T3-L1 cells were treated with kahweol for 48 hours. 
(F) Protein expression of PPAR, C/EBP, FABP4, and FASN was 
detected by western blotting. Protein expression was normalized 
to -actin.
Fig. 2. Kahweol attenuates expression of adipogenic factors. (A) 
Oil Red O staining of kahweol-treated 3T3-L1 cells. After MDI 
induction, 3T3-L1 cells were treated with kahweol on days 2-6. 
Oil Red O staining was conducted on day 6. (B) mRNA 
expression of PPAR, C/EBP, FABP4, and FASN was detected by 
real-time PCR. RNA samples were prepared on days 0, 2, 4, and 
6. 3T3-L1 cells were treated with kahweol on days 2-6. mRNA 
expression was normalized to -actin. ***P ＜ 0.001, DMSO vs. 
kahweol. (C) Protein expression of PPAR, C/EBP, FABP4, and 
FASN was detected by western blotting. Protein samples were 
prepared on days 0, 2, 4, and 6. 3T3-L1 cells were treated with 
kahweol on days 2-6. Protein expression was normalized to 
-actin.
without significant side effects. We used a library using in 
clinic with other purpose to cure diseases, such as antibiotics 
and anti-cancer agents. We established a screening method to 
determine lipid accumulation using 3T3-L1 cells. After 
screening with natural products, we identified kahweol, that is 
a diterpene found in beans of Coffea arabica and structurally 
related to cafestol (Fig. 1A and B). Recent research suggests 
that kahweol may have beneficial effects on bones by 
inhibiting osteoclast differentiation (11). Another recent study 
revealed that kahweol has anti-inflammatory and anti- 
angiogenic effects (12), offering a possible mechanism for 
epidemiological studies revealing a relationship between 
unfiltered coffee intake and decreased risk of cancer.
In this study, we examined kahweol’s effect on adipocyte 
differentiation and lipid accumulation. Because AMP-Activated 
Protein Kinase (AMPK) is an enzyme regulating glucose 
transport and lipid metabolism, AMPK is a therapeutic target of 
diabetic agent anti-and obesity (13). Interestingly, we determined 
that kahweol has a potent effect on activation of AMPK, 
thereby increasing glucose uptake in blood of sugar-taken 
mice. We suggest that kahweol may be an ideal agent for 
obesity attenuation and suggest clinical trials further examine 
potential applications.
RESULTS
Kahweol reduces lipid accumulation in 3T3-L1 cells
Excessive increase of adipocyte number (hyperplasia) and 
adipocyte size (hypertrophy) contributes to obesity. In adults, 
obesity is caused by an increase in adipocyte size in white 
adipose tissue from excessive storage of triglyceride. Inhibition 
of triglyceride accumulation in adipocytes is a promising 
strategy for prevention and treatment of obesity. To not 
influence mitotic clonal expansion, a period when cells 
proliferate during adipocyte differentiation, 3T3-L1 cells were 
treated with different concentration of kahweol 2 days after 
MDI-induction. Lipid accumulation in 3T3-L1 cells was 
measured using Oil Red O staining on day 6 (Fig. 1C). 
Kahweol (25 g/ml) significantly reduced lipid accumulation, 
whereas cafestol did not reduce lipid accumulation (Figs. 1C 
and D). To confirm the inhibitory effect of kahweol on lipid 
accumulation is not a result of cell cytotoxicity, a cell viability 
assay was conducted. We confirmed there was no difference 
in cell viability (Fig. 1E). We tested if kahweol treatment affects 
protein expression of PPAR, C/EBP, FABP4, and FASN, that 
regulate adipocyte differentiation and lipid metabolism. 
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Fig. 3. Kahweol inhibits mitotic clonal expansion and reduces 
lipid droplet size. (A) Oil Red O staining and lipid accumulation 
of kahweol-treated 3T3-L1 cells. 3T3-L1 cells were treated with 
MDI and kahweol for day 2. Oil Red O staining was conducted 
on day 6. (B) Oil Red O staining and lipid accumulation of 
kahweol-treated 3T3-L1 cells. 3T3-L1 cells were treated with 
kahweol on days 6-10. Oil Red O staining was conducted on 
day 10. (C) Increase of cell numbers during mitotic clonal 
expansion. 3T3-L1 cells were treated with DMI and kahweol until 
day 2, and cell numbers were measured on day 0 and 2. *P ＜
0.05, **P ＜ 0.01, ***P ＜ 0.001, untreated control vs. kahweol.
Fig. 4. Kahweol reduces lipid accumulation and increase glucose 
uptake through activation of AMPK. (A) Western blot analysis of 
signal transduction-related proteins. 3T3-L1 cells were treated with 
kahweol on day 2 and incubated for 24 hours. (B) Activity of 
signal transduction-related proteins, such as AMPK and ACC was 
detected by western blotting. 3T3-L1 cells were treated with 
kahweol on day 2. (C) Knockdown of AMPKa1 using small inter-
fering RNA (siRNA). After transfection of AMPKa1 siRNA, 3T3-L1 
cells were incubated with MDI. Then, 3T3-L1 cells were treated 
with kahweol on day 2. ***P ＜ 0.001, scRNA vs. siAMPK. (D) 
Protein expression of PPAR and C/EBP was detected by western 
blotting. Protein samples were prepared on day 4. (E) Glucose 
uptake analysis. 3T3-L1 cells were incubated with kahweol or 
metformin for 48 hours. The remaining level of glucose in media 
was measured using a glucose assay kit. Metformin was used as 
a positive control. *P ＜ 0.05, **P ＜ 0.01, ***P ＜ 0.001, 
untreated control vs. kahweol, untreated control vs. metformin (F) 
Glucose tolerance test (n = 5 for each group). 8 week-old 
C57BL/6 mice were treated with the vehicle (DMSO) or kahweol 
(100 mg/kg) every 2 days via oral administration. After 2 weeks, 
the glucose tolerance test was conducted at 0, 15, 30, 60, 90, 
and 120 minutes. *P ＜ 0.05, vehicle (n = 5) vs. kahweol (n = 5).
Kahweol significantly reduced expression of these proteins in a 
dose-dependent manner (Fig. 1F). 
Kahweol suppresses the expression of adipogenesis and lipid 
accumulation-related genes in 3T3-L1 cells
We identified that 25 g/ml kahweol has an inhibitory effect 
on lipid accumulation through dose-dependent treatment (Fig. 
2A). To examine how kahweol treatment affects adipogenesis 
and lipid accumulation-related genes during adipocyte 
differentiation, cell lysates were prepared on days 0, 2, 4, and 
6. We treated cells with kahweol 2 days after adipogenic 
stimuli, focusing on the effect of kahweol on lipid accumu-
lation. Kahweol significantly repressed mRNA (Fig. 2B) and 
protein expression (Fig. 2C) of PPAR, C/EBP, FABP4, and 
FASN after 2 days of treatment, suggesting that kahweol affects 
adipogenesis and lipid accumulation. 
Kahweol reduces MDI-induced adipocyte differentiation and 
lipid droplet size
To demonstrate the effect of kahweol on MDI-induced 
adipogenesis, 3T3-L1 cells were treated with MDI and kahweol 
at day 0. Kahweol treatment reduced adipocyte differentiation 
and lipid accumulation (Fig. 3A). We also examined the effect 
of kahweol on late adipocyte differentiation. 3T3-L1 cells were 
incubated with kahweol from days 6 to 10. Kahweol treatment 
slightly reduced lipid accumulation, and we revealed lipid 
droplet size in kahweol-treated 3T3-L1 cells was smaller than 
that of control cells (Fig. 3B).
To identify kahweol’s effect on MDI-induced mitotic clonal 
expansion, we measured cell number on day 0 and 2. On day 
2, vehicle-treated 3T3-L1 cell number increased about 1.8-fold 
compared with that in day 0. Kahweol-treated 3T3-L1 cell 
number also increased, compared with that at day 0, but 
increased significantly less than vehicle-treated samples (Fig. 
3C). Data indicate that kahweol represses adipocyte differen-
tiation through inhibition of mitotic clonal expansion and 
reduces lipid droplet size.
Kahweol inhibits lipid accumulation and increase glucose 
uptake through activation of AMPK
Many studies have reported that kahweol suppresses activation 
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of AKT and ERK1/2 (11, 14). AKT and ERK1/2 pathways were 
reported to regulate adipocyte maturation (15). We examined 
changes in activation of these signaling pathways that are 
involved in adipocyte differentiation and lipid metabolism 
(Fig. 4A). Phosphorylation of AKT and JAK2 decreased after 
kahweol treatment; in contrast, phosphorylation of ERK1/2 was 
not affected by kahweol treatment. Interestingly, we found that 
kahweol treatment significantly increased the phosphorylation 
of AMPK and its downstream target Acetyl-CoA carboxylase 
(ACC). We also validated that kahweol treatment increased 
phosphorylated AMPK and ACC in a time-dependent manner 
(Fig. 4B). Many studies have reported that AMPK is activated 
by phosphorylation and that it inhibits adipocyte differen-
tiation and increases glucose uptake and fatty acid oxidation 
(13).
We investigated if kahweol may inhibit lipid accumulation 
through AMPK activation. The inhibitory effect of kahweol on 
lipid accumulation was alleviated by knockdown of AMPK 
using siRNAs (Fig. 4C). Knockdown of AMPK also reduced the 
effect of kahweol on expression of adipogenesis and lipid 
metabolism-related genes (Fig. 4D). These results suggest that 
kahweol suppresses lipid accumulation by up-regulation of 
AMPK activation. Activation of AMPK promotes cellular 
glucose uptake through glucose transporter. Metformin known 
as AMPK activator has an anti-diabetic effect (16). Since 
kahweol also has the effect of AMPK activation as metformin, 
we hypothesized that kahweol may reveal an anti-diabetic 
effect. In 3T3-L1 cells, kahweol treatment elevated glucose 
uptake in a dose-dependent manner (Fig. 4E). In addition, we 
tested if kahweol may improve glucose homeostasis in vivo. 8 
week-old mice were administered kahweol every 2 days by 
oral gavage. After 2 weeks, we conducted glucose tolerance 
test (GTT). Clearance of blood glucose was faster in 
kahweol-treated mice than in control mice (Fig. 4F).
DISCUSSION
Coffee, one of the most consumed beverages globally contains 
a variety of ingredients that are beneficial to health. 
Epidemiological studies suggest that coffee consumption may 
reduce incidence of several chronic diseases such as obesity, 
type 2 diabetes, neurodegenerative diseases, Parkinson’s disease, 
and cardiovascular diseases (17-19). Many studies have 
revealed that coffee consumption decreases accumulation of 
lipid and collagen in the liver and modulates antioxidant and 
inflammatory responses. However, mechanisms for its 
beneficial effects are not fully understood. Coffee intake is 
known to increase cholesterol and the diterpenes cafestol and 
kahweol are implicated in its effect (20). Cafestol and kahweol 
cause extracellular accumulation of LDL by reducing activity 
of hepatic LDL receptors (21).
In this study, we determined the molecular mechanism by 
which kahweol inhibits lipid accumulation in 3T3-L1 cells. 
First, we established a screening method using adipogenesis of 
3T3-L1 cells. We treated cells with selected compounds from 
natural compound libraries 2 days after initiation of adipocyte 
differentiation, then quantified lipid accumulation in adipogenic 
3T3-L1 cells by Oil Red staining. Among these compounds, 
we found that kahweol, a coffee-specific diterpene, has a 
strong anti-lipogenic effect compared to its structural analog 
cafestol. Kahweol inhibited lipid accumulation and adipocyte 
differentiation, but cafestol had no effect on these in 3T3-L1 
cells. Many studies on kahweol have defined its inhibitory 
effects on cancer, angiogenesis, and inflammation. For example, 
kahweol inhibits cell growth by inducing proteasomal 
degradation of cyclin D1 via ERK1/2, JNK, and GKS3- 
dependent phosphorylation (22) and HSP 70 Expression (23) 
in human colorectal cancer. Kahweol induces apoptosis via 
inhibition of STAT3 phosphorylation in human lung adenocar-
cinoma A549 cells (24). The anti-angiogenic effect of kahweol 
on endothelial cells was demonstrated by inhibition of MMP-2 
and uPA expression (12) and inhibition of VEGFR2 signaling 
pathway (25). We detected that kahweol treatment reduced 
the expression of adipogenic factors, such as PPAR and 
C/EBP, that induce adipogenic differentiation, lipid synthesis 
related factor, FASN, and the lipid accumulation promoting 
factor FABP4. 
Interestingly, we determined that kahweol induces activa-
tion of AMPK. AMPK is a serine/threonine kinase, that is a key 
enzyme for maintaining cellular energy homeostasis (13, 26). 
AMPK has a heterotrimer complex consisting ,  and  
subunits. Catalytic  subunit contains Thr172 phosphorylated 
by AMPK upstream kinase. Regulatory  subunit has four 
Cystathionine  synthase (CBS) domains that create two AMP 
binding sites known as the Bateman domain. One of major 
roles of AMPK is the regulation of lipid metabolism. AMPK 
activation phosphorylates and inactivates acetyl-CoA carboxy-
lase, an enzyme involved in fatty acid synthesis, and con-
sequently inhibits synthesis of fatty acid and increases 
-oxidation. AMPK also regulates glucose metabolism. AMPK 
increases glycolysis by activating of 6-phosphofructo-2-kinase/ 
fructose-2, 6-bisphosphatase 2/3 and suppresses glycogen 
synthesis through inhibition of glycogen synthase (13). AMPK 
increases glucose uptake by promoting glucose transporter 4 
and hexokinase 2 expressions in skeletal muscle cells (27, 28). 
AMPK modulates various metabolic processes and its dys-
regulation is commonly observed in type 2 diabetes, obesity, 
and several types of cancer. AMPK activation is a promising 
therapeutic strategy for alleviating metabolic dysfunction. 
Many studies have revealed that AMPK activators inhibit 
adipocyte differentiation in vitro and ameliorate adiposity in 
high-fat diet-fed obese mice (29-31). Metformin, a typical 
AMPK activator is an anti-diabetic drug for therapy of type 2 
diabetes (16). 
In this study, kahweol induces phosphorylation of AMPK. 
The effect of kahweol treatment on reducing lipid accumulation 
was decreased by depletion of AMPK, suggesting that the 
inhibitory effect of kahweol on lipid accumulation was due to 
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phosphorylation of AMPK. Mice were fasted for 15 hours and 
then fed glucose. The blood glucose level of kahweol-pretreated 
mice decreased faster than untreated mice. However, we do 
not know how kahweol increases phosphorylation of AMPK. 
Thr172 phosphorylation of the AMPK -subunit is regulated 
by three phosphatases: Mg2＋/Mn2＋ dependent protein phos-
phatase 1E (PPM1E), protein phosphatase 2A (PP2A), and 
protein phosphatase 2C (PP2C) (13, 32). If AMP/ATP and 
ADP/ATP ratios are low, phosphatases access and dephos-
phorylate Thr172 of AMPK -subunit. Thr172 phosphorylation 
of the AMPK -subunit is also regulated by three upstream 
AMPK kinases: liver kinase B1 (LKB1), calcium/calmodulin- 
dependent kinase 2 (CaMKK2) (33), and TGF-activated kinase 
1 (TAK1) (34). When intracellular energy is low, level of AMP 
and ADP elevates and, AMP and ADP bind to Bateman 
domains of the AMPK -subunit. This leads to conformational 
change that exposes the catalytic domain of AMPK -subunit, 
and prevents access to phosphatases. Residue Thr172 in 
catalytic domain of AMPK -subunit is phosphorylated by 
upstream AMPK kinases. AMPK activation is regulated 
allosterically by competitive binding of ATP and AMP or ADP. 
Currently, we are studying how kahweol regulates phosphory-
lation of AMPK by examining AMPK-related signaling pathways 
and/or the kinases that are regulated by kahweol.
Together, we suggest that kahweol has anti-obesity effects 
and should be studied further for possible therapeutic 
applications.
MATERIALS AND METHODS
Materials and methods are available in supplementary 
information.
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